Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDI-988 in Healthy Adult Participants
NCT05977140Phase 1Completed
- Sponsor
- Cocrystal Pharma
- Start
- Sep 2023
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CDI-988 in coronavirus disease 2019 (COVID-19) (12 cohorts), sponsored by Cocrystal Pharma. Primary endpoints: Adverse Events up to 17 days, Laboratory Abnormalities up to 17 days and 2 more. Started Sep 2023; status: completed.
02
Drugs
CDI-988
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05977140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05977140.